Product information and disease descriptionProduct descriptionProduct information
Generic, brand name and therapeutic class of product
5 evidence topics · 5 sources
Development code and nonproprietary name
Brand name
No evidence found.
Therapeutic class: complete estrogen receptor antagonist and selective estrogen receptor degrader
“Here, we describe our discovery of the investigational drug OP-1250 (palazestrant). OP-1250 is a potent complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) that is active in both WT and mutESR1 breast cancer tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International nonproprietary name: proposed in 2022
“Proposed INN: List 128” (opens the source at this quote in a new tab)
“palazestrantum” (opens the source at this quote in a new tab)
“antiestrogen, antineoplastic” (opens the source at this quote in a new tab)
“C28H36FN3O” (opens the source at this quote in a new tab)
“2092925-89-6” (opens the source at this quote in a new tab)